Nav1.5(Late) cardiac safety assay on QPatch
As an alternative to standard pharmacological procedures for NaV1.5(Late) assays, we present a more reliable and accurate NaV1.5(Late) assay on QPatch that removes the requirement for activators like veratridine and ATX-II and delivers improved cardiac safety screening reliability and cost.
- High fidelity QPatch recordings of small amplitude NaV1.5 (Late) currents from Long QT3 syndrome mutant channels.
- Stable recordings without pharmacological activators allow more reliable drug potency assessment.
- Pharmacologically validated with sodium channel blockers with a preference for the NaV1.5(Late).